Novartis Update EHA 2017 Effective Iron Chelation with Exjade® as the Key Factor for the Treatment Success

被引：0

|

作者：

不详

机构：

来源：

TRANSFUSION MEDICINE AND HEMOTHERAPY | 2017年 / 44卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页数：1

相关论文

共 12 条

[1] EHA Update 2017 New Data on the Benefits of Novartis Ruxolitinib (Jakavi®) in Polycythemia vera and Myelofibrosis
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (05) : 372 - 372
[2] REVIEU-Study Real-Life-Data for the Treatment of chronic ITP with Novartis' Revolade® is presented at the EHA 2017
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (05) : 372 - 372
[3] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis.
Angelucci, E
Turlin, B
Canatan, D
Mangiagli, A
De Sanctis, V
Meddeb, B
Rose, C
Soulieres, D
Cunningham, M
Gattermann, N
Ressayre-Djaffer, C
Rabault, B
Ford, J
BLOOD, 2005, 106 (11) : 757A - 758A
[4] Exjade® (Deferasirox) Novartis' Film-Coated Tablet has simplified the Treatment of transfusion-related Iron Overload for one Year
Nothing, Pia
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (06) : 431 - 431
[5] IRON CHELATION-THERAPY IN CAPD - A NEW AND EFFECTIVE TREATMENT OF IRON OVERLOAD DISEASE IN ESRD PATIENTS
STANBAUGH, GH
HOLMES, AW
GILLIT, D
REICHEL, GW
STRANZ, M
PERITONEAL DIALYSIS BULLETIN, 1983, 3 (02): : 99 - 101
[6] Recommendations and guidelines on influenza vaccination and treatment - A key success factor
van Essen, G. A.
Winclak, Adam
Kossow, Klaus-Dieter
Treanor, John
Brotons, Carlos
VACCINE, 2006, 24 (44-46) : 6783 - 6784
[7] Preventive Maintenance: The Key Factor for Long-term Treatment Success
Sculean, Anton
ORAL HEALTH & PREVENTIVE DENTISTRY, 2015, 13 (04) : 287 - 287
[8] Cardiac iron overload in patients with beta thalassaemia major: continued improvement and normalization of myocardial T2*with up to 3 years deferasirox (Exjade) oral iron chelation treatment
Pennell, D. J.
EUROPEAN HEART JOURNAL, 2011, 32 : 986 - 986
[9] Deferasirox (Exjade®) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice: Results From the Observational Studies Extend and Exjange
Gattermann, Norbert
Leismann, Oliver
Schlag, Rudolf
Blumenstengel, Klaus
Goebeler, Mariele
Groschek, Matthias
Losem, Christoph
Procaccianti, Maria
Stern, Sieglinde
Nass, Alexia
Germing, Ulrich
BLOOD, 2009, 114 (22) : 1463 - 1464
[10] THE PROCEEDINGS OF THE 17th INTERNATIONAL CONFERENCE ON CHELATION: APPLICATION OF EFFECTIVE CHELATION THERAPIES IN IRON LOADING AND NON IRON LOADING CONDITIONS, AND THE GAP IN THE PREVENTION AND TREATMENT POLICIES ON THALASSEMIA BETWEEN DEVELOPED AND DEVELOPING COUNTRIES
Kontoghiorghes, George J.
HEMOGLOBIN, 2009, 33 (05) : 283 - 286